WASHINGTON (AP) — Drug companies Affymax Inc. and Takeda Pharmaceutical Co. have issued a recall of their anemia drug Omontys after reports of severe allergic reactions in some kidney dialysis patients, including some deaths.

The companies said that more than 25,000 patients have received Omontys, which is used against anemia in patients undergoing kidney dialysis.

The companies said that 0.2 percent of the patients who have received the drug, or about 50, have reported severe allergic reactions and around 0.02 percent of patients, or about five, have died following their first dose of the drug.

The serious hypersensitivity reactions occur within 30 minutes of the drug being administered for the first time. The companies said that no such reactions have been reported subsequent times that the drug is administered to a patient.

The companies said that dialysis centers should stop using Omontys and that customers will be provided with instructions on how to return the product to the manufacturer for a refund. Customers with questions can call 1-855-466-6689 from 9:00 a.m. to 5:00 p.m. EST Monday through Friday. The two companies said they were working with the U. S. Food and Drug Administration on the details of the recall.

About News.net

Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.

 

FAQs

Email

If you have any questions or concerns please email us on support@news.net

Phone

  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.

Cancel